VERU vs VOR

Veru Inc. vs Vor Biopharma Inc. — Valuation Comparison 2026

VERU

Biotechnology
Veru Inc.
Quality
4.6
out of 10
Value Trap
25
LOW
Price
$2.32
Last close
Models
7/13
Active
VS

VOR

Biotechnology
Vor Biopharma Inc.
Quality
3.5
out of 10
Value Trap
30
LOW
Price
$15.01
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType VERU Fair ValueVERU Upside VOR Fair ValueVOR Upside
Bayesian DCF Intrinsic $1.49 -35.8% $5.72 -61.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.71 +60.1% $2.73 -80.8%
PWERM Option-Based $2.56 +10.1% $25.80 +71.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VERU vs VOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VERU vs VOR — Which Stock Is More Undervalued?

VERU scores higher with a 4.6/10 quality rating vs VOR's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Veru Inc. (VERU) and Vor Biopharma Inc. (VOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VERU currently trades at $2.32 with a QOC of 4.6/10, while VOR trades at $15.01 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).